Medication info
Pregabalin 300 mg Capsule

Pregabalin 300 mg Capsule

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›300mg / 1 capsule
Manufacturer / importer
Hanin Pharmaceutical Co., Ltd.
Appearance
A hard capsule with a reddish-brown upper part and a white lower part containing a white or pale yellow powder.
Packaging
30 capsules/bottle, 100 capsules/bottle, (export 30 capsules (10 capsules/PTP × 3))
Approval status
Active

MFDS item code 201707653 · Approved 2017.10.30 · Insurance code 657203290

Summary

Main use
Treatment of neuropathic pain and fibromyalgia, and adjunctive treatment of partial seizures in epilepsy
Who takes it
Adults · Children
Adult dose
This medicine is administered orally as pregabalin, in 2 divided doses per day, regardless of food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See “5. Patients with Renal Impairment”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See “4. Discontinuation of Treatment”) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ∼ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. Creatinine clearance (ml/min)* *: For women, multiply the result obtained from the above equation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function ≥60: Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30 -<60: Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15 -<30: Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: Initial dose 25 mg, maximum dose 100 mg, single dose TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a : The total daily dose (mg/day) should be divided as specified in the dosing regimen. b : The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescents aged 12 to 17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Hanin Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia, and adjunctive treatment of partial seizures in epilepsy

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication effectively treats peripheral and central neuropathic pain in adults and is used as an adjunctive therapy for partial seizures in patients with epilepsy. It also helps in the treatment of fibromyalgia. Overall, it is utilized in managing neurological disorders and pain, improving the quality of life for patients.

How to take

Adult dose

This medicine is administered orally as pregabalin, in 2 divided doses per day, regardless of food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See “5. Patients with Renal Impairment”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See “4. Discontinuation of Treatment”) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ∼ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. Creatinine clearance (ml/min)* *: For women, multiply the result obtained from the above equation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function ≥60: Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30 -<60: Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15 -<30: Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: Initial dose 25 mg, maximum dose 100 mg, single dose TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a : The total daily dose (mg/day) should be divided as specified in the dosing regimen. b : The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescents aged 12 to 17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so careful monitoring for depression or abnormal mood changes is necessary while taking it. Patients with a hypersensitivity to this drug should not take it. Diabetic patients may need to adjust the dosage of their blood sugar control medications due to weight gain. If allergic reactions such as angioedema occur, the medication should be discontinued immediately. Elderly patients should be cautious initially, as dizziness or drowsiness may be more pronounced. There may be changes in vision, such as blurriness; in such cases, discontinuing the medication may improve the symptoms. Care should be taken when switching from other antiepileptic drugs to this medication alone. Withdrawal symptoms such as insomnia, headaches, nausea, and anxiety may occur if the medication is stopped abruptly. Patients with a history of substance abuse should be particularly cautious due to the risk of drug abuse. Patients with decreased kidney function may require dosage adjustments. Patients with heart conditions should use this medication with caution. Taking this medication with opioid analgesics may increase central nervous system depressant effects, so caution is warranted. Patients with compromised respiratory function or the elderly may be at risk for severe respiratory depression, so dosage adjustments may be necessary. During early pregnancy, there may be risks to the fetus, so women of childbearing potential should use effective contraception, and it is advisable to avoid the medication during pregnancy. Breastfeeding women are advised to discontinue breastfeeding or the medication as it may be transferred through breast milk. Caution is needed when driving or operating hazardous machinery due to the risk of dizziness or drowsiness. Severe skin reactions may occur rarely, so notify a healthcare provider immediately if skin abnormalities occur. In case of overdose, symptoms such as confusion, drowsiness, and depression may appear, requiring immediate medical attention.

Side effects

  • suicidal thoughts
  • suicidal behavior
  • depression
  • angioedema
  • facial edema
  • perioral edema
  • upper respiratory edema
  • dizziness
  • drowsiness
  • loss of consciousness
Show 173 more
  • confusion
  • mental disorder
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • suicidal ideation
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • respiratory function impairment
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • flatulence
  • excessive salivation
  • gastroesophageal reflux
  • oral sensory impairment
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweats
  • muscle cramps
  • joint pain
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasm
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urinary disorders
  • incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • nipple discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling intoxicated
  • sensation abnormalities
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • hyperreactivity
  • elation
  • decreased libido
  • depersonalization
  • hypersensitivity
  • anxiety
  • mood swings
  • emotional blunting
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • inability to inhibit
  • apathy
  • ataxia
  • coordination abnormalities
  • balance disorders
  • amnesia
  • attention deficit
  • memory impairment
  • tremors
  • speech disorders
  • sensory abnormalities
  • sensory reduction
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • language disorders
  • myoclonic jerks
  • decreased reflexes
  • motor abnormalities
  • psychomotor agitation
  • positional vertigo
  • sensory hyperreactivity
  • burning sensation
  • tremors during activity
  • syncope
  • confusion
  • hypokinesia
  • olfactory abnormalities
  • loss of taste
  • writing disorders
  • diplopia
  • auditory hyperreactivity
  • first-degree heart block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • pharyngeal tension
  • nasal dryness
  • respiratory depression
  • keratitis
  • pulmonary edema
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • confused state
  • agitation
  • restlessness
  • worsening of spasms

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air and moisture from entering and should be kept at room temperature between 15 to 30 degrees Celsius. Proper storage will help maintain the medication's efficacy over time.

Appearance and packaging

Appearance

A hard capsule with a reddish-brown upper part and a white lower part containing a white or pale yellow powder.

Package unit

30 capsules/bottle, 100 capsules/bottle, (export 30 capsules (10 capsules/PTP × 3))

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.